secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001937653-24-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks reports FY 2023 net loss of $118.7M; zanidatamab BLA initiated; cash runway into 2027
--------------------------------------------------------------------------------

- Revenue $76.0M vs $412.5M in 2022, reflecting non-recurring Jazz upfront; net loss of $118.7M vs net income $124.3M.
- Cash, cash equivalents and marketable securities $456.3M as of Dec 31; with milestone payments, runway into 2H 2027.
- Rolling BLA for zanidatamab in second-line biliary tract cancers started by Jazz; expected completion 1H 2024.
- Jazz initiated Phase 3 confirmatory trial for zanidatamab as first-line BTC; BeiGene expects NMPA BLA filing 2H 2024.
- Targeting two IND submissions in 2024 (ZW191, ZW171); ZW49 Phase 2 deprioritized pending collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765324000017/0001937653-24-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765324000017/zyme-20240306.htm
  HTML page:      https://secwatch.observer/filing/0001937653-24-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer